Director/PDMR Shareholding

2 Feb 2009 07:00



30 January 2009

Ark Therapeutics Group plc (the "Company")

Director Shareholding

On 5 January 2009, the Company's Remuneration Committee (which is comprised wholly of non-executive directors) awarded options over 350,000 ordinary shares to the Consultant Director of Molecular Medicine, Professor Seppo Ylä-Herttuala, under the Company's Consultancy Share Option Plan (the "Consultancy Plan").

Options will not be exercisable until at least three years from the date of issue. Options awarded under the Consultancy Plan have an exercise price of 39.25 pence per ordinary share. No consideration was paid for the grant of options.

Following this award, Professor Ylä-Herttuala will hold options over 899,999 ordinary shares.

For further information please contact: